Clinical Trials Browser

Phase 2/3 × Triple Negative Breast Neoplasms × olaparib × Clear all

NCT03150576 2022-11-14

PARTNER

Phase 2/3 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms